SCHEMBL11947239

SCHEMBL11947239

N#Cc1ncnc2c1CN(Cc1ccccc1)CC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.53
ALDH1A1 P00352 5/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 4/20 0.53
HPGD P15428 3/20 0.53
GLA P06280 1/20 0.53
GAA P10253 1/20 0.53
NPSR1 Q6W5P4 2/20 0.51
HIF1A Q16665 1/20 0.51
MEN1 O00255 3/20 0.49
CASP1 P29466 2/20 0.46
CASP7 P55210 2/20 0.46
HSD17B10 Q99714 2/20 0.46
THRB P10828 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
C5AR1 P21730 1/20 0.46
ADORA1 P30542 1/20 0.46
CLPP Q16740 2/20 0.46
ACHE P22303 1/20 0.45
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4985015 0.90 ALDH1A1 (0.53) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL1911807 0.83 KMT2A (0.52) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL30767848 0.81 KMT2A (0.53) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL322777 0.81 KMT2A (0.53) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL1911808 0.80 KMT2A (0.52) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL14872729 0.80 KMT2A (0.52) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL2868214 0.80 KMT2A (0.59) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL16510168 0.78 BRS3 (0.49) KDM4EALDH1A1KMT2AMAPTHPGD
SCHEMBL11947240 0.77 KMT2A (0.49) KDM4EALDH1A1KMT2AMAPTGAA
SCHEMBL998652 0.77 C5AR1 (0.68) KMT2AMEN1C5AR1CLPPACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373163-B1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2015-06-10 EP disclosed
US-8232273-B2 Heterocyclic compounds and methods of use GENENTECH, INC. (US) 2012-07-31 US disclosed
US-8232273-B2 Heterocyclic compounds and methods of use GENENTECH, INC. (US) 2012-07-31 US disclosed
US-20100210622-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE ABBVIE INC. 2010-08-19 US disclosed
US-20100210622-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE ABBVIE INC. 2010-08-19 US disclosed
WO-2010080503-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210622-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE BCL2A1, BAX, BCL2 KDM4E 1311/4885ALDH1A1 3017/4885KMT2A 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.